The critical role of intratumoral and gut microbiota in modulating cancer biology is increasingly recognized, impacting processes from inflammation and metabolism to therapy resistance. Traditional 2D cell cultures fail to capture the nuanced, spatially organized interactions between human cells and microbes. Tumor organoid cocultures bridge this gap by establishing a physiologically relevant human-derived 3D tumor ecosystem. This platform allows for the controlled introduction of bacteria, fungi, or viruses, facilitating the direct investigation of microbial colonization, pathogenicity, metabolite exchange, and immune modulation within a native tumor context. It serves as a powerful tool for deciphering causal relationships and mechanistic pathways in microbiome-oncology research.
Coculture systems can be broadly classified based on the nature of the microbial partner and the experimental design. The categorization reflects the diversity of host-microbe interactions relevant to different cancer types and research questions.
Organoid Microinjections
This technique directly introduces microbes into the organoid lumen, which provides a physiologically relevant hypoxic environment ideal for anaerobic bacteria. It enables sustained, multi-day cocultures of challenging organisms like Fusobacterium nucleatum or Clostridioides difficile.
Basal Organoid Cocultures
This basolateral side can be targeted by simply adding the microbial components to the culture medium. However, this requires the microbial agents to diffuse through the extracellular matrix domes to reach the organoids. Thus, it might be more suitable to study the effects of microbial metabolites or toxins rather than larger objects like living bacteria.
Transwell Models
In transwell models, organoids are cultured on a culture insert with a porous membrane, typically coated with an ECM-like gel, creating a 2D monolayer of cells. This design makes both the apical and basal sides easily accessible and leads to the formation of two compartments separated by cells seeded on the insert membrane.
Organ-on-a-Chip Platforms
Microfluidic systems integrate organoids or epithelial layers into dynamic channels, enabling precise control over fluid flow, shear stress, and oxygen gradients. This makes them ideal for modeling complex, multi-step processes like bacterial colonization, epithelial invasion, and immune cell recruitment in response to infection.
Leveraging expertise in tumor organoid generation, stringent microbiological control, and advanced 3D culture technologies, Alfa Cytology provides end-to-end experimental support, from model establishment and microbial characterization to functional readouts and high-content imaging. Our services are designed to deliver physiologically relevant, reproducible, and scalable co-culture models that meet specific research and drug screening objectives.
Alfa Cytology offers high-precision platforms designed to simulate the complex interplay between the microbiome and the tumor microenvironment. By integrating advanced bioengineering with organoid technology, we provide specialized modeling systems that address your unique research needs, enabling deep mechanistic insights into microbial-driven oncogenesis, metabolic interference, and immune modulation across diverse diseases.
By Methods
Alfa Cytology provides end-to-end, customized research services leveraging advanced tumor organoid-microbe coculture platforms. Our solutions are designed to transform this sophisticated technology into reliable data for your oncology and microbiome research, supporting studies from mechanistic investigation to therapeutic discovery.
Focused on decoding the causal relationships between microbes and cancer biology, these services employ controlled co-culture systems for deep mechanistic investigation. Specific microbial influences on oncogenic signaling, tumor microenvironment remodeling, immune modulation, and cancer phenotypic hallmarks are elucidated to provide foundational insights for novel target discovery.
Designed to translate fundamental discoveries into therapeutic applications, these services utilize physiologically relevant co-culture models to generate predictive drug development data. Critical evaluation of compound efficacy, safety, and pharmacokinetics within the context of the human tumor microbiome is enabled, de-risking candidates and informing further trial design prior to in vivo studies.
Alfa Cytology developed a glioblastoma organoid and human cytomegalovirus (HCMV) co-culture model to investigate the role of viral infection in brain tumors. Glioblastoma organoids were first established from specimens, which reliably recapitulated the histopathological features of the original tumor. These organoids were then pre-treated with a selective EphA2 antagonist before being exposed to HCMV. Following the co-culture period, advanced molecular analysis confirmed a significant, dose-dependent reduction in viral replication within the treated glioblastoma organoids. These results successfully established a physiologically relevant model that not only elucidated a key host-virus interaction mechanism but also identified EphA2 blockade as a promising therapeutic strategy, demonstrating the utility of our co-culture platform in target discovery and validation for oncology research.
Fig.1 Quantification of HCMV infection in glioblastoma organoids treated with an EphA2 receptor antagonist. Data are presented as mean ± SEM (n=3; ***p < 0.001).
Alfa Cytology's integrated service provides a cutting-edge, physiologically relevant platform to explore the critical interface between tumors and the microbiome. By offering end-to-end custom model development, execution, and advanced analytical readouts, we empower your research with scientific insights. Contact our scientific team to discuss how Tumor Organoid Cocultures with Microbes can be tailored to accelerate your specific oncology program.
References
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.
